Skip to main content
Publications
Quinn KL, Abdel-Qadir H, Barrett K, Bartsch E, Beaman A, Biering-Sorensen T, Colacci M, Cressman A, Detsky A, Gosset A, Lassen MH, Kandel C, Khaykin Y, Lapointe-Shaw L, Lovblom E, MacFadden DR, Perkins B, Rothman KJ, Skaarup KG, Stall N, Tang T, Yarnell C, Zipursky J, Warkentin MT, Fralick M, COVID-ACE Group. Variation in the risk of death due to COVID-19: an international multicenter cohort study of hospitalized adults. J Hosp Med. 2022 Oct 1;17(10):739-802. doi: 10.1002/jhm.12946
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.